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Early Cardiac Effects of Contemporary Radiation Therapy in Breast Cancer Patients  1 
ABSTRACT 2 
PURPOSE: To characterize the early changes in echocardiographic-derived measures of 3 
cardiac function with contemporary radiation therapy (RT) in breast cancer and determine the 4 
associations with radiation dose-volume metrics including mean heart dose (MHD).  5 
METHODS AND MATERIALS: In a prospective longitudinal cohort study of 86 breast cancer 6 
patients treated with photon or proton thoracic RT, clinical and echocardiographic data were 7 
assessed at three time points: within 4 weeks before RT initiation (T0); within 3 days prior to 6 8 
weeks after the end of RT (T1), and 5-9 months after RT completion (T2). Associations between 9 
MHD and echocardiographic-derived measures of cardiac function were assessed using 10 
generalized estimating equations to define the acute (T0 to T1) and subacute (T0 to T2) 11 
changes in cardiac function.  12 
RESULTS: The median (IQR) estimates of MHD ranged from 139 cGy (99 – 249 cGy). In 13 
evaluating the acute changes in LVEF from T0 to T1, and in accounting for the time from RT, 14 
age, race, pre-existing cardiovascular disease, and an interaction term with anthracycline and/or 15 
trastuzumab exposure and MHD, there was a modest decrease in LVEF of borderline 16 
significance (0.22%, 95% CI -0.44%, 0.01%; p=0.06, per 30-day interval for every 100 cGy 17 
increase of MHD). Similarly, there was a modest worsening in longitudinal strain (0.19%, 95% 18 
CI -0.01%, 0.39%; p=0.06), per 30-day interval for each 100 cGy increase in MHD. We did not 19 
find significant associations between MHD and changes in circumferential strain or diastolic 20 
function.  21 
CONCLUSION: With modern radiation planning techniques, there are very modest subclinical 22 
changes in measures of cardiac function in the short-term. Longer-term follow-up studies are 23 
needed to determine if these early changes are associated with the development of overt 24 





Radiation therapy (RT) is fundamental to breast cancer treatment, resulting in important 2 
reductions in disease morbidity and mortality (1). However, thoracic RT can potentially lead to 3 
increased cardiovascular morbidity and mortality. Historical data from 1954 to 1984 suggest that 4 
those treated with RT had a 1.76 fold (95% CI 1.34, 2.31) increased risk of cardiovascular death 5 
(2). A seminal population-based case-control study by Darby et al. demonstrated that the risk of 6 
a major coronary event increased proportionally with mean heart dose (MHD) without an 7 
apparent threshold to the risk (3). These studies have defined the late cardiac effects of RT, 8 
which may present years after RT exposure (4-6). The cardiac effects of RT in the short-term 9 
may be less clear, with several recent smaller studies reporting inconsistent findings related to 10 
the relationship between RT exposure and cardiac function (7-10). Moreover, in the modern 11 
treatment era, the cardiac side effects of RT may be decreased due to improvements in 12 
radiation planning and delivery that reduce heart dose (11).  13 
To clarify the early cardiac effects of contemporary RT in breast cancer patients, we 14 
performed detailed echocardiographic phenotyping prior to, immediately following, and 5-9 15 
months after thoracic RT exposure in a prospective longitudinal cohort study, the XXXX (XXXX) 16 
study. Specifically, we sought to determine the changes in cardiac function that occur acutely 17 
and subacutely following RT exposure in breast cancer patients and the associations with MHD. 18 
We hypothesized that thoracic RT results in a dose-dependent worsening of cardiovascular 19 
function as defined by echocardiographic-derived measures of left ventricular ejection fraction 20 
(LVEF), longitudinal and circumferential strain, and diastolic function.  21 
 22 
METHODS 23 




 We prospectively enrolled breast cancer patients newly initiating photon or proton 1 
thoracic RT from the Department of Radiation Oncology at the XXXX from June 2015 to 2 
January 2018. Inclusion criteria were age greater than 18 years old; left or right-sided breast 3 
cancer newly initiating fractionated whole-breast/chest wall RT with an expected cardiac dose or 4 
regional nodal photon or proton RT; or right-sided breast cancer with internal mammary nodal  5 
RT who were newly starting fractionated photon or proton RT were also included with an 6 
expected cardiac dose. The expected cardiac dose was determined by the treating radiation 7 
oncologist, with the goal of enrolling patients who would have any expected more than minimal 8 
risk heart dose from whole breast RT on the left, or regional internal mammary node treatment 9 
on either side. Patients were included regardless of exposure to adjuvant chemotherapy, 10 
neoadjuvant chemotherapy, and/or targeted therapy. Also, patients with a history of prior 11 
contralateral breast radiation without cardiac involvement were eligible for recruitment. Patients 12 
were excluded if they had prior RT to the thoracic region that would result in overlap of RT 13 
fields; life expectancy less than 12 months; lack of echocardiographic imaging due to lack of 14 
baseline echocardiograms or poor acoustic windows; or inability to comprehend English. The 15 
study was approved by the XXXX Institutional Review Board. 16 
 17 
Study procedures 18 
Detailed clinical data, demographics, cardiovascular, and oncologic history were 19 
collected using standardized patient and physician questionnaires and verified through medical 20 
records review. We obtained these data at three time points: within 4 weeks before RT (T0), 21 
within 3 days prior to the end of RT to 6 weeks after the end of RT (T1), and 5-9 months after 22 
RT completion (T2) (Figure 1). In our analysis, we defined acute changes as those from T0 to 23 





Cardiac radiation exposure 1 
Study patients underwent planning computed tomography (CT) or positron emission 2 
tomography (PET/CT) simulation with appropriate positioning and immobilization with or without 3 
deep inspiratory breath-hold (DIBH) technique as per institutional standard of care. 4D CT data 4 
were used to ascertain if the patient would benefit from DIBH by evaluating the relative heart 5 
position compared to the breast clinical target volume of the maximum inhaled CT phase and 6 
compared to maximum exhaled CT phase. DIBH was used when possible. Normal anatomic 7 
structures were contoured by dosimetrists. Radiation target volumes and margins were 8 
contoured by the treating radiation oncologist using the standardized contouring protocol based 9 
on Radiotherapy Comparative Effectiveness Consortium (RADCOMP) atlas (12-14). Radiation 10 
treatment planning using 3-D conformal, intensity-modulated radiation therapy (IMRT) or proton 11 
therapy was performed by dosimetrists/medical physicists using institutional dose constraints, 12 
which are based on modern Radiation Therapy Oncology Group (RTOG) dose guidelines (15). 13 
After completion of the radiation plan, dose parameters to organs-at-risk were extracted from 14 
dose-volume histograms, including MHD, and the percent volume of heart receiving incremental 15 
radiation doses (e.g., V5 Gy, V20 Gy). All dosimetry calculations were performed using Eclipse 16 
Treatment Planning System v 15.6 (Varian Medical Systems, Palo Alto, CA, USA). 17 
 18 
Quantitative Echocardiography 19 
Two-dimensional and Doppler echocardiography were performed on Vivid E9 or E95 20 
machines (GE Healthcare, Milwaukee, WI) according to a standard research protocol. Images 21 
were quantified in a blinded manner by sonographers at the XXXX Center for Quantitative 22 
Echocardiography using the TomTec® Imaging Systems platform (Unterschleissheim, 23 
Germany). LVEF was calculated using biplane Simpson’s method of discs using left ventricular 24 




and circumferential strain were quantified on images, digitally archived at 60-80 frames per 1 
second, using vendor-independent software (Cardiac Performance Analysis, TomTec Imaging 2 
Systems). Diastolic dysfunction was assessed by measurement of transmitral flow parameters 3 
(early transmitral flow (E), late transmitral flow (A), deceleration time), tissue Doppler indices of 4 
mitral annular velocity (septal and lateral e’), left atrial volume indexed to body surface area 5 
(LAVI) and tricuspid regurgitation (TR) velocity. Average E/e’ is a measure of diastolic function, 6 
which represents the early transmitral inflow divided by the average of the septal and lateral 7 
tissue Doppler indices e’. This ratio is often used as a measure of left-sided cardiac filling 8 
pressures. Estimates of the intraobserver coefficient of variation were 4.4% for LVEF, 10.9% for 9 
longitudinal strain, and 9.4% for circumferential strain (17,18). The intraobserver coefficients of 10 
variation for mitral inflow and tissue Doppler velocities were 2.3% to 5.4% (19). All quantitation 11 
was performed by observers blinded to patient characteristics and timing of echocardiograms. 12 
 13 
Statistical Analysis 14 
Standard descriptive statistics were used to characterize the study population at 15 
baseline using proportions for categorical variables and mean (standard deviation) and median 16 
(interquartile range (IQR)) for normally and non-normally distributed continuous variables, 17 
respectively. Differences in echocardiographic measures at T0 and T1 (acute), as well as T0 18 
and T2 (subacute), were tested with the Wilcoxon signed-rank test. Differences in 19 
echocardiographic measures across all three time points were tested with the Kruskal-Wallis 20 
test. We evaluated the following echocardiographic outcomes: LVEF, longitudinal strain, 21 
circumferential strain, and E/e’. 22 
 We then assessed the multivariable associations between changes in each 23 
echocardiographic measure and MHD in the acute (T0 to T1) and subacute (T0 to T2) time 24 




correlation structure for the longitudinal observations of echocardiographic measures. GEE was 1 
chosen as we wanted to quantify the population-level associations between change of cardiac 2 
function and MHD, although sensitivity analyses using linear mixed models was also performed. 3 
Days from RT was calculated as the time from the first day of initiating RT therapy as a 4 
continuous variable. For each model, confounders were selected based on a combination of 5 
statistical evidence with clinical and biological judgment. We a priori hypothesized that the effect 6 
of MHD on cardiac function was not constant over time, and thus modeled the changes from T0 7 
to T1 and T2 separately. We also hypothesized that the association between MHD and 8 
echocardiographic-derived measures of cardiac function would differ according to systemic 9 
cancer therapy exposure, and explored the interaction between cancer therapy (anthracyclines, 10 
trastuzumab) and MHD at baseline (20,21). 11 
We developed three sequential models: Model 1 included the longitudinal assessments 12 
of our echocardiographic variable of interest as the outcome, MHD, time from radiation 13 
treatment, and a time by exposure interaction with MHD as our primary variable of interest; 14 
Model 2 included the variables in Model 1 in addition to baseline (T0) echocardiographic 15 
parameter, age, race, pre-existing cardiovascular disease, anthracycline and/or trastuzumab 16 
exposure. Pre-existing cardiovascular disease was defined as a history of hypertension, 17 
hyperlipidemia, diabetes, coronary artery disease including a history of angina or previous 18 
myocardial infarction, arrhythmias, heart failure, known history of reduced ejection fraction, or 19 
cardiac surgery; Model 3, the fully adjusted model, included variables in Model 2 and an 20 
interaction term with anthracycline or trastuzumab exposure and MHD. All tests were two-sided; 21 
the type I error rate was set at 0.05. Statistical analyses were performed using STATA V.15.1 22 
(StataCorp, College Station, TX) (22). Graphics were generated using the ggplot2 package in R 23 
version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria) (23). Assuming a 24 




estimated to provide >80% power to detect an absolute change relative to baseline as low as 1 
1.0% for LVEF, longitudinal strain, and circumferential strain at a two-sided significance level of 2 
5%.  3 
RESULTS 4 
Study population 5 
Eighty-six female patients were enrolled (Table 1). The mean age at enrollment was 53 6 
± 11.4 years; the median was 54 years [IQR 44, 62 years]. At baseline, 68 (79.1 %) had primary 7 
left-sided breast cancer, 10 (11.6%) had primary right-sided breast cancer, 3 (3.5%) had 8 
recurrent breast cancer, and 5 (5.8%) had bilateral breast cancer. Overall, 9 patients (10.5%) 9 
had stage 0, 18 (20.9%) had stage I, 32 (37.2%) had stage II, and 26 (30.2%) had stage III 10 
breast cancer (24). There were 18 patients (20.9%) who had no systemic cancer therapy as part 11 
of their current treatment regimen; however, 48 (55.8%) had only anthracycline exposure, 20 12 
(23.3%) had trastuzumab exposure, and 11 (12.8%) had both anthracycline and trastuzumab 13 
exposure. 14 
Of the 86 patients with analyzable echocardiograms at baseline (T0), 79 patients were 15 
evaluated at T1, and 83 evaluated at T2. The median time from RT initiation to T1 was 56 days 16 
[IQR 43, 72 days], and T2 was 223 days [IQR 196, 259 days]. Seventeen additional studies 17 
from sixteen individual patients were performed for clinical indications outside the prespecified 18 
timepoints and included in the analyses. These additional studies were primarily performed for 19 
standard monitoring indications during trastuzumab therapy. Two studies occurred between T0 20 
and T1 (17 and 29 days after RT) and 15 studies occurred between T1 and T2 visits (median 21 
148 days after RT, [IQR 121, 168 days]). 22 
 23 




Across the entire cohort, the median MHD was low, at 139 cGy [IQR 99, 249 cGy] with a 1 
range of 2-789 cGy. In patients with primary left-sided breast cancer, the median MHD was 142 2 
cGy [IQR 104, 264 cGy]; in primary right-sided breast cancer, the MHD was 86 cGy [IQR 34, 3 
129 cGy]; in bilateral breast cancer, the MHD was 210 cGy [IQR 181, 302 cGy]; and in recurrent 4 
breast cancer, the MHD was 115 cGy [IQR 103, 288 cGy]. The primary RT technique was 3D 5 
conformal (tangential fields) in 61 patients (70.9%), 12 patients (14.0%) had IMRT (tangential 6 
fields), 9 patients (10.5%) had scanning proton radiation, and 4 patients (4.7%) had passive 7 
scattering proton radiation using either two or three non-tangential fields. The median time 8 
between RT initiation and completion was 40 days (IQR 30, 44 days]. Thirty-seven patients had 9 
motion management techniques used during RT therapy with a median MHD was 144 cGy [IQR 10 
115, 327 cGy] compared to 120 cGy [IQR 99, 224 cGy] in those without motion management 11 
techniques. A majority (28 patients) utilized DIBH with a median MHD 205 cGy [IQR 119, 360 12 
cGy], 8 patients were placed in prone positioning with MHD 109 cGy [IQR 91, 128 cGy], and 1 13 
subject had abdominal compression with MHD of 186 cGy. Sixty-two out of 86 patients (72.0%) 14 
had boost radiation with 6 patients (7.0%) having proton therapy, 40 patients (46.5%) having 15 
photon therapy, and 16 patients (18.6%) having electron therapy. The median total RT dose 16 
was 5256 cGy [IQR 5040, 6000 cGy] with a median dose of initial fields of 5000 cGy [IQR 4256, 17 
5040 cGy]. A median cone down dose of 1000 cGy [IQR 1000, 1000 cGy] was used when 18 
clinically indicated. 19 
 20 
Changes in systolic function pre-RT (T0), immediately after RT (T1), and 5-9 months after 21 
RT (T2) 22 
Changes in echocardiographic markers over time from baseline are presented in Figure 23 
2 and Table 2. First, we examined longitudinal patterns in echocardiographic measures over 24 




likely reflective of the effects of anthracyclines and/or trastuzumab therapy administered prior to 1 
RT. At T0, 21 patients of 86 had a quantitated LVEF less than 50% at baseline, prior to RT. The 2 
median LVEF in this subgroup was only mildly decreased at 48.0% [IQR 44.9%, 48.9%]. At T1, 3 
the median LVEF was 51.5% [IQR 48.0%, 54.1%], and at T2 was 52.4% [IQR 49.9%, 55.3%] 4 
(Table 2). There was a modest decrease in the absolute LVEF from T0 to T1 of -1.8% (95% CI -5 
2.8%, -0.7%; p=0.01). However, there was no significant difference in the LVEF from T0 to T2 6 
(Figure 2A, Table 2). 7 
At T0, the median longitudinal strain was -15.6% [IQR -18.1%, -13.1%], again likely 8 
reflective of the cardiotoxic effects of anthracyclines and/or trastuzumab therapy. At T1, the 9 
median longitudinal strain was -15.6% [IQR -18.9%, -13.7%] and at T2 longitudinal strain was -10 
16.8% [IQR -20.2%, -14.9%]. There were no differences in longitudinal strain between T0 and 11 
T1 with a mean change in longitudinal strain of -0.5% (95% CI -1.4, 0.4; p=0.33). However, 12 
between T1 and T2, there was a very modest improvement in longitudinal strain that was of 13 
borderline statistical significance (mean change -0.9%; 95% CI -1.7%, -0.1%; p=0.06). In 14 
comparing T0 and T2, longitudinal strain was also improved at T2 with a mean change in 15 
longitudinal strain of -1.8% (95% CI -2.6, -0.9; p=0.003) (Figure 2B). The median circumferential 16 
strain changes over time are detailed in Table 2; there were no differences in circumferential 17 
strain between T0 and T1 or T2 (Figure 2C).  18 
 19 
Associations between echocardiographic measures of systolic function and mean heart 20 
dose  21 
We next determined the associations between the absolute change in LVEF and MHD 22 
accounting for the time from RT exposure. Here, the reported beta coefficients represented the 23 




RT exposure (Table 3). Between T0 and T1, there were no significant associations in our 1 
unadjusted and minimally adjusted models in GEE analysis. Accounting for confounders and the 2 
interaction between MHD and anthracyclines and/or trastuzumab exposure in Model 3, there 3 
was a borderline significant 0.22% decrease in LVEF (95% CI -0.44%, 0.01%; p=0.06) per 30-4 
day interval for every 100 cGy increase of RT exposure from T0 to T1. This translates to an 5 
annualized decrease in LVEF of 2.6% (95% CI -5.3%, 0.1%) at T1 compared to T0 for every 6 
100 cGy of RT exposure. There was no association between MHD and the rate of change in 7 
LVEF from T0 to T2. Additionally, we present the regression coefficients of the explored 8 
interaction term between MHD (per 100 cGy) and anthracycline and/or trastuzumab exposure in 9 
the Supplement Table S5. In these exploratory analyses, trastuzumab was observed to be an 10 
effect modifier of the cross-sectional associations between MHD and cardiac function.  11 
For longitudinal strain, we found no significant associations between MHD and the rate 12 
of change in strain in the acute unadjusted and minimally adjusted models from T0 to T1. In the 13 
acute fully adjusted model (Model 3) there was a modest worsening in longitudinal strain, of 14 
borderline statistical significance, at 30 days for each 100 cGy increase in MHD on the order of 15 
0.19% (95% CI -0.01%, 0.39%; p=0.06) (Table 3) which translates into an annualized worsening 16 
in longitudinal strain of 2.3% (95% CI -0.1%, 4.7%). Between T0 and T2, there were no 17 
subacute associations between longitudinal strain and MHD. Furthermore, there were no 18 
associations with MHD and rate of change in circumferential strain from T0 to T1 or from T0 to 19 
T2. 20 
In additional sensitivity analyses evaluating the association between V5, V10, and V20 21 
and longitudinal and circumferential strain, our findings were similar (Supplemental Tables S1-22 
3). We performed additional analyses evaluating the association between acute changes in 23 




associations (Supplemental Table S4). Finally, sensitivity analyses using fully adjusted linear 1 
mixed models showed similar associations as in our GEE analyses (Supplemental Table 6). 2 
 3 
Changes in diastolic function pre-RT, immediately after RT and 5-9 months after RT  4 
There were no overall differences in E/e’ throughout follow-up (Figure 2D, Table 2). The 5 
median E/e’ at T0 was 7.9 (IQR 6.6, 10.3); at T1 was 8.3 (IQR 6.7, 9.9); and at T2 was 8.1 (IQR 6 
6.8, 10.8). There was a decrease in left atrial volume indexed to body surface area (LAVI) from 7 
22.9 ml/m2 (IQR 20.0, 27.5) at T0 to 20.5 ml/m2 (IQR 16.6, 24.3) at T2 (p=0.006). There were 8 
no changes in E/e’, E/A, or other diastolic function parameters at the three time points (Table 2).  9 
 10 
Associations between echocardiographic measures of diastolic function and mean heart 11 
dose  12 
In our multivariable GEE analysis (Table 3), there were no acute associations between 13 
E/e’ and MHD between T0 and T1. In evaluating the unadjusted associations between E/e’ and 14 
MHD from T0 to T2, there was a very small increase in average E/e’ of 0.07 (95% CI 0.001, 15 
0.13; p = 0.05) per 30-day interval for every 100 cGy of RT exposure. In multivariable models, 16 
the effect size was similar, although this association was not statistically significant. We again 17 
performed additional sensitivity analyses evaluating the association between V5, V10, and V20 18 
and diastolic dysfunction, and our findings were similar (Supplemental Table S1-3). 19 
 20 
DISCUSSION 21 
  In this prospective longitudinal cohort study of 86 breast cancer patients, we evaluated 22 




With modern radiation planning techniques, the MHD is low. We observed three main findings: 1 
1) there was a slight worsening in LVEF acutely after RT that recovered over time; 2) there was 2 
no change in longitudinal strain, circumferential strain, or E/e’ immediately after RT; 3) the 3 
associations between MHD and core-lab quantified measures of systolic function (LVEF, 4 
longitudinal strain) were modest, demonstrating only a slight decrease in cardiac function per 5 
100 cGy increase in MHD. Our results suggest that the short-term, adverse effects of RT in 6 
breast cancer on subclinical measures of cardiovascular function are overall very modest.  7 
We found a small decrease in LVEF in the acute time period from pre-RT to immediately 8 
post RT, which recovered in the subacute period 5-9 months post-RT, and an association 9 
between MHD exposure and change in LVEF that was of borderline statistical significance. 10 
Other smaller, retrospective studies (N=47) have also reported significant changes in measures 11 
of LVEF but did not determine an association with MHD (25). We hypothesize that the smaller 12 
sample size of these other studies and the limited power, as well as the small effect sizes, may 13 
explain the disparate findings. 14 
Consistent with our findings above, we also determined a weak association between 15 
longitudinal strain and MHD in our multivariable analyses. We also observed an abnormal pre-16 
RT longitudinal strain that we hypothesize is reflective of the effects of anthracycline 17 
chemotherapy (18). Prior studies evaluating longitudinal strain have primarily focused on 18 
chemotherapy or targeted therapy naïve patients receiving a greater MHD. For example, Lo et 19 
al. studied left-sided breast cancer patients treated with breast-conserving surgery who were 20 
chemotherapy naïve and only treated with adjuvant RT with a mean MHD of 250 ± 130 cGy and 21 
no nodal RT (26). Over six-weeks of follow-up, there was a reduction in global and segmental 22 
systolic strain parameters compared with baseline assessments with the most significant 23 
decrement in the left ventricle (LV) apical segments. Similar findings were observed by 24 




RT(28). Altogether, these data suggest that in the acute period following RT exposure, there are 1 
small changes in LVEF and longitudinal strain that are likely dose dependent. The clinical 2 
significance of these changes remains to be determined, and longer-term follow-up is needed. 3 
 We did not find an association between MHD and the change in circumferential strain in 4 
our analysis, consistent with previously published studies (7,25). Circumferential strain tends to 5 
be reflective of a more advanced stage of cardiac injury and remodeling (17), also consistent 6 
with these findings.  7 
We also did not identify changes in indices of diastolic function. Our longitudinal data 8 
analysis did demonstrate an association between MHD and E/e’ in the subacute period in our 9 
minimally adjusted models, which was no longer significant after multivariable adjustment. The 10 
literature regarding changes in diastolic dysfunction after RT exposure has been mixed or not 11 
reported (8,9,25,29,30). The pathophysiology of RT leading to diastolic dysfunction remains to 12 
be fully elucidated, as does the question of whether small changes in diastolic function 13 
contribute to clinical disease (31). 14 
  The cardiovascular concerns of complications from modern-day RT may be less 15 
significant than the historical literature, particularly with the current advances in RT delivery and 16 
low MHD. We attribute the results of our study primarily to the successes in minimizing cardiac 17 
exposure in thoracic RT with cardiac contouring and with the increased use of DIBH techniques 18 
and some patients receiving proton therapy. Of note, the MHD in our longitudinal study was 19 
significantly lower than the previously reported series (7,9,10,26,32-35). 20 
 21 
Strengths and Limitations 22 
The strengths of this study included the large sample size compared with the previous 23 




quantitated echocardiographic outcome measures, as well as the use of a prospective 1 
longitudinal study design. To date, studies assessing acute radiation cardiotoxicity have had 2 
small patient numbers without the use of contemporary RT techniques and anticancer regimens 3 
(7,26). Our study design and patient enrollment more accurately reflect current chemotherapy 4 
and RT practices for breast cancer more so than previously reported in the literature (7-5 
10,26,32,33). The XXXX cohort had a high retention rate with minimal missing data (< 5%).  6 
Limitations included a relatively short median follow-up time of 7.3 months after RT, but 7 
our focus is on early changes immediately post RT. Although larger than previously reported 8 
studies, our sample size was still small, limiting statistical power and the ability to perform a 9 
detailed comparison of proton and photon RT. We included all patients regardless of 10 
chemotherapy or targeted therapy history to enhance the generalizability of our findings. 11 
However, we acknowledge that we cannot fully differentiate the effects of RT from the effects of 12 
cardiotoxic systemic cancer therapy, given our relatively small sample size. We adjusted for 13 
anthracycline and trastuzumab exposure in our multivariable models but acknowledge that this 14 
may not fully account for the complex interactions between systemic cardiotoxic therapy and 15 
RT, particularly given toxicity is known to be dose-dependent. We did not include cardiac 16 
subsite-specific analysis such as left anterior descending artery exposure, left ventricle, and 17 
right ventricle, given the limited MHD exposure, but this should be considered in future studies. 18 
Our cohort was enrolled at a tertiary center with state-of-the-art imaging-guided RT delivery 19 
techniques, limiting generalizability to the broader population of breast cancer patients.  20 
 21 
CONCLUSIONS  22 
 This study provides insight into several knowledge gaps in breast cancer patients 23 
undergoing systemic cancer therapy and RT. In the era of contemporary thoracic RT for breast 24 




exposure is minimal and likely related to the low MHD. Longer-term follow-up studies are 1 
needed to understand if these subclinical changes are clinically relevant and if they contribute to 2 
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Figure 1 - XXXX (XXXX) study design. Patient clinical data, demographics, cardiovascular, and 
oncologic history were assessed at three time points: within 4 weeks before RT (T0); within 3 
days prior to the end of RT to 6 weeks after the end of RT (T1), and 5-9 months after RT 
completion (T2). RT was typically an 8-week course with a median of 40 days of treatment, RT 
= Radiation Therapy 
 
Figure 2 - Changes in echocardiographic measures (LVEF, longitudinal strain, circumferential 
strain, and E/e’) from baseline values after RT therapy.  Gray lines represent the trajectory of 
each echo variable plotted for each individual subject. Blue lines indicate summary Loess 
smoothing splines which represent the mean change in each echocardiographic measure with 
point-wise confidence bands.  Changes for each echocardiographic variable are represented in 
A) LVEF (%), B) Longitudinal strain (%), C) Circumferential strain (%), and D) E/e’. For 
longitudinal and circumferential strain, which are negative values, a decrease from baseline 
represents an improvement in strain, for example, from -15.6 to% -16.8%. E/e’ = diastolic 





Table 1 - Patient Characteristics  
  Count (%) or Median [IQR]† 
 Age at diagnosis (years) 54 [44,62] 
 Race  
      Caucasian 62 (72.1) 
      Black or African American 21 (24.4) 
      Asian/Pacific Islander 3 (3.5) 
Baseline BMI, kg/m2 28.4 [23.6,32.8] 
Current or past smoking 36 (41.9) 
Cardiovascular history   
     Hypertension 29 (33.7) 
     Diabetes Mellitus 10 (11.6) 
     Hyperlipidemia 23 (26.7) 
     Coronary artery disease (CAD) 4 (4.7) 
     History of heart failure (HF) 5 (5.8) 
     Pre-existing cardiovascular disease or risk factors** 45 (52.3) 
     ACEI/ARB or beta-blocker use at baseline 29 (33.7) 
Breast Cancer Site  
     Primary left 68 (79.1) 
     Primary right  10 (11.6) 
     Recurrent  3 (3.5) 
     Bilateral 5 (5.8) 
AJCC Breast Cancer Stage   
     Stage 0 9 (10.5) 
     Stage 1 18 (20.9) 
     Stage 2 32 (37.2) 
     Stage 3 26 (30.2) 
Anthracycline (AC) or trastuzumab (T) exposure  
     Neither AC nor T  18 (20.9) 
     Anthracycline 48 (55.8) 
     Trastuzumab   20 (23.3) 
     Both AC and T 11 (12.8) 
Primary radiation technique  
    Protons (passive scattering)  4 (4.7) 
    Protons (scanning) 9 (10.5) 
    3D Conformal 61 (70.9) 
    IMRT 12 (14.0) 
 Mean Heart Dose (MHD) (cGy) 139 [99,249] 
 V5 cGy Heart Dose (%) 2.8 [1.3,8.5] 
 V10 cGy Heart Dose (%) 1.1 [0.2, 3.9] 
 V20 cGy Heart Dose (%) 0.35 [ 0.01, 1.6] 
 LVEF baseline (%) 53.0 [50.0, 55.8] 
 Longitudinal strain baseline (%) -15.6 [-18.1, -13.1] 
 Circumferential Strain baseline (%) -23.5 [-27.6, -19.7] 
 E/e’ average baseline 7.9 [6.6,10.3] 
Abbreviations:3D = 3-dimensional; AC = anthracycline; ACEi = angiotensin-converting enzyme 
inhibitor; AJCC = American Joint Committee on Cancer; ARB = angiotensin receptor blocker; BMI = 




IMRT = intensity-modulated radiation therapy; MHD = mean heart dose; RT = radiation therapy; T = 
trastuzumab  
† Categorical variables were summarized with count (%); all continuous variables were summarized 
with the median [interquartile range] 
** Pre-existing cardiovascular disease was defined as the diagnosis or history of hypertension, 
hyperlipidemia, diabetes, coronary artery disease including a history of angina or previous myocardial 






Table 2 - Echocardiographic Parameters Pre-RT (T0), Immediately Post-RT (T1) and 5-9 months 













N = 86 N = 79 N = 83 
LVEF (%)  53.0 [50.0, 55.8] 51.5 [48.0, 54.1] ‡ 52.4 [49.9, 55.3] 0.04 
Longitudinal strain (%)  -15.6 [-18.1, -13.1] -15.6 [-18.9, -13.7] -16.8 [-20.2, -14.9]** 0.01 
Circumferential Strain (%)  -23.5 [-27.6, -19.6] -24.1 [-29.0, -20.9] -24.5 [-30.3, -20.4] 0.30 
Left Atrial Volume Index mL/m2  22.9 [20.0, 27.5] 22.0 [18.8, 25.0] 20.5 [16.6, 24.3]** 0.02 
E wave (cm/s)  74.0 [62.0, 90.0] 78.5 [64.0, 91.0] 74.0 [62.0, 83.0] 0.52 
A wave (cm/s)  68.0 [58.0, 82.5] 70.5 [58.0, 86.0] 71.0 [57.0, 83.0] 0.96 
LV Lateral Velocity e wave (cm/s)  10.0 [8.0, 12.0] 10.0 [8.0, 12.0] 10.0 [8.0, 12.0] 0.36 
LV Lateral Velocity a wave (cm/s)  10.0 [8.0, 11.0] 9.0 [8.0, 10.0] 9.0 [7.0, 10.0] 0.21 
LV Septal Velocity e wave (cm/s)  7.0 [6.0, 10.0] 8.0 [6.0, 10.0] 7.0 [6.0, 10.0] 0.29 
LV Septal Velocity a wave (cm/s)  9.0 [7.0, 10.0] 8.5 [7.0, 10.0] 8.0 [8.0, 10.0] 0.72 
LV e' mean velocity (cm/s) 8.5 [7.0, 10.8] 9.3 [7.8, 11.0] 9.0 [7.0, 10.5] 0.33 
E/e’ average 7.9 [6.6, 10.3] 8.3 [6.7, 9.9] 8.1 [6.8, 10.8] 0.81 
E/A 1.1 [0.8, 1.4] 1.1 [0.8, 1.3] 1.0 [0.8, 1.3] 0.83 
 
Abbreviations:A = late transmitral flow; E = early transmitral flow; E/A = ratio of early and late 
transmitral flows, diastolic function index; E/e’ = early transmitral inflow divided by the average of the 
septal and lateral tissue Doppler indices e’, diastolic function index;  LV = Left Ventricle; LVEF = Left 
Ventricular Ejection Fraction. 
† P-values represent differences in values between all three-time points tested with the Kruskal-Wallis 
test.  
‡ Differences in values between prior to RT (T0) and immediately after RT (T1) were statistically 
significant (p<0.05) according to the Wilcoxon signed-rank test. 
** Differences in values between prior to RT (T0) and 5-9 months after RT (T2) were statistically 





Table 3 - Associations between the Rate of Change in Longitudinal Strain, Circumferential Strain, LVEF and E/e’ with Mean Heart 
Dose** 
  LVEF Longitudinal strain  Circumferential Strain  E/e’ 
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0.08 (-0.14,  
0.31) 
0.45 -0.23 (-0.70, 
0.23) 










0.15 (-0.04,  
0.34) 
0.12 -0.20 (-0.59, 
0.19) 












0.06 -0.18 (-0.57, 
0.20) 














0.70 0.04 (-0.04, 
0.20) 
0.30 0.07 (-0.07, 
0.20) 
0.33 0.07 (0.001, 
0.13) 






0.54 0.05 (-0.03, 
0.13) 











0.44   0.05 (-0.03, 
0.13) 






** Beta coefficients, 95% Confidence Interval (CI) are reported as per each 100 cGy exposure over 30 days; all changes represent absolute 
differences. 
The unadjusted model (Model 1) included the echocardiographic variable of interest over time as our outcome measure, MHD, time from 
radiation treatment, and time by treatment interaction with MHD as our primary variable of interest.. The minimally adjusted model (model 2) 
included the variables in Model 1 in addition to adjusting for the baseline (T0) echocardiographic variable, age, race, pre-existing cardiovascular 
disease, as well as anthracycline and/or trastuzumab exposure prior to RT. The fully adjusted model (Model 3) included the variables in models 
1, 2 and an interaction term with anthracycline or trastuzumab exposure and MHD  
§ Due to issues of collinearity, E/e’ models for acute changes were not adjusted for baseline E/e’ in Models 2 and 3 
Abbreviations: CI = Confidence Interval; E/e’ = diastolic function index; LVEF = left ventricular ejection fraction; MHD = Mean Heart Dose; RT = 
Radiation Therapy
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